Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.07 USD
Change Today -0.09 / -7.76%
Volume 439.6K
XXII On Other Exchanges
Symbol
Exchange
Stuttgart
As of 4:15 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

22nd century group inc (XXII) Snapshot

Open
$1.19
Previous Close
$1.16
Day High
$1.19
Day Low
$1.06
52 Week High
06/16/14 - $3.87
52 Week Low
02/25/15 - $0.65
Market Cap
75.8M
Average Volume 10 Days
418.6K
EPS TTM
$-0.23
Shares Outstanding
70.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for 22ND CENTURY GROUP INC (XXII)

Related News

No related news articles were found.

22nd century group inc (XXII) Related Businessweek News

No Related Businessweek News Found

22nd century group inc (XXII) Details

22nd Century Group, Inc., a plant biotechnology company, focuses on tobacco harm reduction and smoking cessation products produced from modifying the nicotine content in tobacco plants through genetic engineering and plant breeding. It develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes which reduce exposure to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. The company’s products include RED SUN and MAGIC regular and menthol cigarettes; and SPECTRUM government research cigarettes. It is also developing X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy; and modified risk cigarettes, such as BRAND A, which has approximately 95% less nicotine than tobacco in cigarettes, as well as BRAND B cigarettes that contains low amount of tar per milligram of nicotine. The company was founded in 1998 and is based in Clarence, New York.

23 Employees
Last Reported Date: 02/6/15
Founded in 1998

22nd century group inc (XXII) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $200.0K
Chief Financial Officer and Treasurer
Total Annual Compensation: $180.0K
Vice President, General Counsel and Secretary
Total Annual Compensation: $326.2K
Vice President of R&D
Total Annual Compensation: $185.0K
Compensation as of Fiscal Year 2014.

22nd century group inc (XXII) Key Developments

22nd Century Group Appoints Nora B. Sullivan to its Board

22nd Century Group, Inc. announced that the Company appointed Nora B. Sullivan to 22nd Century Group's Board of Directors, effective May 18, 2015. Ms. Sullivan has made a career of applying her legal experience and financial services expertise to focus on strategic planning, corporate governance matters, and M&A services. Ms. Sullivan is currently President of Sullivan Capital Partners, LLC.

22nd Century Group, Inc. Announces Earnings Results for the First Quarter Ended March 31, 2015

22nd Century Group, Inc. announced earnings results for the first quarter ended March 31, 2015. For the quarter, net revenue was $616,000 compared to $448,000 of net revenue for the three months ended March 31, 2014. The first quarter 2015 net revenues of $616,000 were generated from the manufacture and sale of a third-party MSA cigarette brand, filtered cigars, and own proprietary cigarette brand, RED SUN. Operating loss of $4.1 million as compared to an operating loss in the amount of $1.2 million for the three months ended March 31, 2014. The Company’s net loss for the three months ended March 31, 2015 was $4.1 million, or $0.06 per share, as compared to a net loss of $5.3 million, or $0.09 per share, for the three months ended March 31, 2014; a decrease in the net loss of approximately $1.2 million. The reduction in the net loss is primarily attributable to a decrease in the non-cash change in the fair value of derivatives (warrant liability) in the approximate amount of $4.1 million, partially offset by the $2.9 million increase in the operating loss discussed in the previous paragraph. Adjusted EBITDA for the three months ended March 31, 2015 was a negative $1.5 million, or $0.02 per share, and a negative $0.8 million, or $0.01 per share, for the three months ended March 31, 2014.

22nd Century Group, Inc., Q1 2015 Earnings Call, May 12, 2015

22nd Century Group, Inc., Q1 2015 Earnings Call, May 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XXII:US $1.07 USD -0.09

XXII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GlaxoSmithKline PLC 1,454 GBp -6.50
Imperial Tobacco Group PLC 3,370 GBp -2.00
Lorillard Inc $72.48 USD -0.04
Perrigo Co PLC $190.30 USD -3.66
Reynolds American Inc $76.75 USD -0.03
View Industry Companies
 

Industry Analysis

XXII

Industry Average

Valuation XXII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 106.7x
Price/Book 6.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 100.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 22ND CENTURY GROUP INC, please visit www.xxiicentury.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.